Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

Mayo Clinic Proceedings

Volumn 86, Issue 5, 2011, Pages 444-456

  Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROPOIETIN; EXENDIN 4; EZETIMIBE; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; RAMIPRIL; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ALBUMINURIA; ANEMIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DOSE TITRATION; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INSULIN TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SCREENING; SMOKING CESSATION; SYNCOPE; WEIGHT REDUCTION;

EID: 79955668545     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0713     Document Type: Review

References (130)

1. Centers for Disease Control and Prevention (CDC). National Diabetes Fact Sheet, 2007. www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed January 28, 2011.
2. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79-S83.
3. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2)(suppl 2):S12-S154.
4. US Renal Data System (USRDS). Annual data report: 2009. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009. http://www.usrds.org/adr-2009.htm. Accessed January 28, 2011.
5. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31(11):2608-2617.
6. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673-682.
7. Laliberté F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm. 2009;15(4):312-322.
8. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4(8):444-452.
9. Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007; 30(8):1998-2000. (Pubitemid 47219407)
10. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol. 1993;3(8):1458-1466.
11. Balakumar P, Arora MK, Reddy J, Anand-Srivastava MB. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol. 2009;54(2):129-138.
12. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2(3):581-590.
13. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426. (Pubitemid 32681484)
14. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl. 2004 Nov;(92):S59-S62. (Pubitemid 43361433)
15. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813-1821.
16. So WY, Kong AP, Ma RC, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006;29(9):2046-2052. (Pubitemid 44871185)
17. El Nahas M. Cardio-kidney-damage: a unifying concept. Kidney Int. 2010;78(1):14-18.
18. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106-2111. (Pubitemid 44141899)
19. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed- Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32(4):219-226. (Pubitemid 19136363)
20. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med. 2006;26(3):635-653. (Pubitemid 44287154)
21. Nobel MIM, Drake-Holland AJ. Hyperglycaemia and the vascular glycocalyx: the key to microalbuminuria and cardiovascular disease in diabetes mellitus? Br J Diabetes Vasc Dis. 2010;10(2):66-70.
22. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. Bone. 2009;45(suppl 1):S26-S29.
23. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
24. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
25. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
26. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33(suppl 1):S11-S61.
27. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353(9153):617-622. (Pubitemid 29087981)
28. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. (Pubitemid 36159355)
29. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591. (Pubitemid 351214285)
30. Saran R, Hedgeman E, Plantinga L, et al. Establishing a national chronic kidney disease surveillance system for the United States. Clin J Am Soc Nephrol. 2010;5(1):152-161.
31. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3(2):A57.
32. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16(1):180-188.
33. Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Adv Chronic Kidney Dis. 2010;17(3):225-236.
34. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc. 2008;83(12):1373-1381.
35. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med. 2008;25(suppl 2):25-29. (Pubitemid 352020092)
36. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273-3277. (Pubitemid 37430080)
37. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27(1):195-200. (Pubitemid 38196732)
38. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470. (Pubitemid 29135798)
39. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254. (Pubitemid 46768608)
40. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
41. 2. Am J Kidney Dis. 2010;56(3):486-495.
42. Levey AS, de Jong PE, Coresh J, et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report [published online ahead of print December 8, 2010]. Kidney Int. doi: 10.1038/ki.2010.483.
43. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 1999;22(11):1887-1898. (Pubitemid 29521879)
44. Phisitkul K, Hegazy K, Chuahirun T, et al. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci. 2008;335(4):284-291. (Pubitemid 351548647)
45. Cignarelli M, Lamacchia O, Di Paolo S, Gesualdo L. Cigarette smoking and kidney dysfunction in diabetes mellitus. J Nephrol. 2008;21(2):180-189.
46. Chuahirun T, Simoni J, Hudson C, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci. 2004;327(2):57-67. (Pubitemid 38220468)
47. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 2004;27(suppl 1):S74-S75.
48. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep. 2007;7(6):449-453. (Pubitemid 350284976)
49. Ting SM, Nair H, Ching I, Taheri S, Dasgupta I. Overweight, obesity and chronic kidney disease. Nephron Clin Pract. 2009;112(3):c121-c127.
50. Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications. 2010;24(6):368-374.
51. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010;25(4):1173-1183.
52. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27(8):2067-2073. (Pubitemid 38989258)
53. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
54. Bakris GL, Sowers JR; American Society of Hypertension Writing Group. Treatment of hypertension in patients with diabetes - an update. J Am Soc Hypertens. 2010;4(2):62-67.
55. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
56. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-1589.
57. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-2572. (Pubitemid 351831357)
58. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2):129-139.
59. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
60. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389.
61. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
62. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. (Pubitemid 351831356)
63. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010; 33(5):983-990.
64. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444.
65. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340(5):b4909.
66. 1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481-489.
67. Cheung BMY, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443-453.
68. Kramer H, Molitch ME. Screening for kidney disease in adults with diabetes. Diabetes Care. 2005;28(7):1813-1816. (Pubitemid 40923104)
69. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121-1127.
70. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17(5):365-370. (Pubitemid 39422090)
71. Glucophage (metformin hydrochloride) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb; January 2009. http://packageinserts.bms.com/pi/pi- glucophage.pdf. Accessed January 28, 2011.
72. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579. (Pubitemid 126537875)
73. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010;12(12):1079-1083.
74. Starlix (nateglinide) tablets [prescribing information]. Stein, Switzerland: Novartis Pharmaceuticals; July 2008. www.pharma.us.novartis.com/ product/pi/pdf/Starlix.pdf. Accessed January 28, 2011.
75. Prandin (repaglinide) tablets [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals; May 2010. www.prandin.com/docs/prandin-insert.pdf. Accessed January 28, 2011.
76. Precose (acarbose tablets) [package insert]. Wayne, NJ: Bayer Health- Care Pharmaceuticals; August 2008. www.univgraph.com/Bayer/inserts/Precose.pdf. Accessed January 28, 2011.
77. Glyset miglitol tablets [prescribing information]. New York, NY: Pfizer; revised October 2010. www.pfizer.com/files/products/uspi-glyset.pdf. Accessed January 28, 2011.
78. Actos (pioglitazone hydrochloride) tablets [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America; August 2008. http://general. takedapharm.com/content/file/pi.pdf?applicationcode=8a9c4571-a123-4477-91de- b9cafe7d07e3&filetypecode=actospi. Accessed January 28, 2011.
79. Avandia (rosiglitazone maleate) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2008. http://us-gsk.com/ products/assets/us-avandia.pdf. Accessed January 28, 2011.
80. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta- analysis. Am J Kidney Dis. 2010;55(5):835-847.
81. Byetta (exenatide injection) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals; October 2009.http://pi.lilly.com/us/byetta-pi.pdf. Accessed January 28, 2011.
82. Victoza (liraglutide [rDNA origin] injection), solution for subcutaneous use [prescribing information]. Princeton, NJ: Novo Nordisk Pharmaceuticals; January 2010. www.victozapro.com/pdf/victoza-comboPI-5.24.pdf. Accessed January 28, 2011.
83. Januvia (sitagliptin) tablets [prescribing information]. Pavie, Italy: Merck Sharp & Dohme (a subsidiary of Merck & Co); February 2010. http:// www.merck.com/product/usa/pi-circulars/j/januvia/januvia-pi.pdf. Accessed January 28, 2011.
84. Onglyza (saxagliptin) tablets [package insert]. Princeton, NJ: Bristol- Myers Squibb; July 2009. http://packageinserts.bms.com/pi/pi-onglyza.pdf. Accessed January 28, 2011.
85. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786-794.
86. Wajchenberg BL. β-Cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218. (Pubitemid 46984834)
87. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
88. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412-419. (Pubitemid 30609443)
89. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155(10):1073-1080.
90. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed). 1987;294(6585):1443-1447. (Pubitemid 17079619)
91. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346(8982):1080- 1084.
92. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
93. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755-1762. (Pubitemid 28269185)
94. Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med. 1996;335(22):1636-1642. (Pubitemid 26392728)
95. Kalaitzidis R, Bakris G. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009;11(11):636-643.
96. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M. The early natural history of nephropathy in type 1 diabetes; III: predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes. 2005;54(7):2164-2171. (Pubitemid 40911280)
97. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004;44(5):637-642. (Pubitemid 39435232)
98. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
99. Kalaitzidis R, Bakris GL. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009;11(7):345-347.
100. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142(5):342-351. (Pubitemid 40293407)
101. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918-929.
102. Roy M, Mahmood N, Rosendorff C. Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease. Curr Atheroscler Rep. 2010;12(2):134-139.
103. Ruilope L, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk - implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007;16(2):72-79. (Pubitemid 47053774)
104. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
105. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
106. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
107. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. (Pubitemid 351688350)
108. Hopkins KA, Bakris GL. Lower blood pressure goals in high-risk cardiovascular patients: are they defensible? Cardiol Clin. 2010;28(3):447-452.
109. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54-B64. (Pubitemid 30185779)
110. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40-51.
111. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50.
112. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
113. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
114. Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol. 2009;4(2):361-368.
115. Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res. 2010;33(2):100-110.
116. Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008;28(5):723-731.
117. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293-301. (Pubitemid 30429874)
118. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084-2091. (Pubitemid 36909916)
119. Zoppini G, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009;19(8):580-586.
120. Ozsoy RC, van der Steeg WA, Kastelein JJ, Arisz L, Koopman MG. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant. 2007;22(6):1578-1586. (Pubitemid 47073755)
121. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-794.e10.
122. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131-1139.
123. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-734. (Pubitemid 38901488)
124. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605- 1613. (Pubitemid 36687063)
125. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006-2016. (Pubitemid 44036185)
126. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448-1454. (Pubitemid 351471787)
127. Luk AO, Yang X, Ma RC, et al. Association of statin use and development of renal dysfunction in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010;88(3):227-233.
128. Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother. 2010;11(5):723-730.
129. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66(2):753-760. (Pubitemid 38982019)
130. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121(24):2694-2701.